10-Q: Nexien BioPharma Reports Q3 2025 Results Amidst Going Concern Uncertainty

Nexien BioPharma reports its Q3 2025 results, highlighting a net loss and ongoing concerns about the company's ability to continue as a going concern without additional funding.

Summary

• Nexien BioPharma, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025.
• The company is engaged in pre-clinical and drug development activities for pharmaceutical formulations that include cannabinoids.
• The company has incurred an operating loss of $11,636,041 since inception.
• At March 31, 2025, the company had a working capital deficit of $450,516.
• The company requires significant additional capital to fund its business plan, with no current commitments or known sources for this funding.
• The net loss for the three months ended March 31, 2025, was $30,092, compared to a net loss of $53,163 for the three months ended March 31, 2024.
• The net loss for the nine months ended March 31, 2025, was $101,568, compared to a net loss of $152,599 for the nine months ended March 31, 2024.
• The company had outstanding convertible notes in the principal amounts of $70,000 to its CEO and a shareholder, and $207,120 to Quick Capital as of March 31, 2025.
• The company's auditors have issued an opinion describing the company's going concern status.
• Management is seeking merger, business combination, or restructuring opportunities.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's going concern status, lack of revenue, and need for additional funding. While the net loss has decreased, the overall financial situation remains precarious.

Positives

• The net loss decreased for both the three and nine months ended March 31, 2025, compared to the same periods in 2024.
• General and administrative costs decreased for the nine months ended March 31, 2025, compared to the same period in 2024, primarily due to non-cash stock-based compensation costs in the prior year.

Negatives

• The company has a significant accumulated deficit of $11,636,041 since inception.
• The company has a working capital deficit of $450,516.
• The company has ceased research and development activities due to a lack of sufficient working capital.
• The company's independent auditors have issued an opinion describing the company's going concern status.
• The company requires a minimum of $40,000 to maintain its public company status for the remainder of the current fiscal year.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company has no current commitments or known sources for the significant additional capital required to fund its business plan.
• The company's drug development projects are subject to regulatory approval, which may not be obtained.
• The company may not be successful in raising additional funds through equity capital and/or debt financings.
• Additional equity financing may be dilutive to existing stockholders.
• Debt or equity financing may subject the company to restrictive covenants and significant interest costs.
• The company's disclosure controls and procedures were deemed ineffective as of the end of the period covered by the report.

Future Outlook

The company anticipates needing to raise at a minimum $40,000 just to maintain its existence as a public company for the remainder of the current fiscal year and is seeking merger or other business combination or restructuring opportunities.

Management Comments

• Management continues its efforts to raise additional capital for the Company.
• Management is also seeking merger or other business combination or restructuring opportunities.

Industry Context

The company operates in the biopharmaceutical industry, specifically focusing on cannabinoid-based medications, which is a growing but highly competitive and regulated market.

Comparison to Industry Standards

• Given Nexien's stage of development and lack of revenue, it is difficult to directly compare it to established pharmaceutical companies.
• However, similar early-stage biopharmaceutical companies often rely on venture capital or strategic partnerships to fund their research and development activities.
• The company's reliance on convertible debt and related party loans is not uncommon for small companies but can create financial risks.
• Compared to companies like GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) which successfully developed and commercialized cannabinoid-based drugs, Nexien is at a very early stage and faces significant challenges in securing funding and navigating the regulatory process.

Related Party Transactions

• The company's Chief Executive Officer has advanced $98,400 to the Company for working capital and operating purposes.
• The company had outstanding convertible notes in the principal amounts of $70,000 to its CEO and a shareholder as of March 31, 2025.
• The members of the Company's Board of Directors, its Chief Executive Office and its Chief Financial Officer are also directors and officers of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees may be impacted by the company's financial instability and potential restructuring.
• The company's ability to develop and commercialize drugs is uncertain, impacting potential future customers.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to seek additional equity or debt capital.
• The company will explore merger or other business combination or restructuring opportunities.
• The company will attempt to maintain its public company status.

Key Dates

Keywords

biopharma, cannabinoids, drug development, going concern, convertible notes, financial results, net loss, working capital, capital raise, Nexien